Departamento de Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brazil.
PLoS One. 2013 Jun 14;8(6):e67658. doi: 10.1371/journal.pone.0067658. Print 2013.
Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disease characterized by symptoms attributable to the death of striatal and cortical neurons. The molecular mechanisms mediating neuronal death in HD involve oxidative stress and mitochondrial dysfunction. Administration of 3-nitropropionic acid (3-NP), an irreversible inhibitor of the mitochondrial enzyme succinate dehydrogenase, in rodents has been proposed as a useful experimental model of HD. This study evaluated the effects of probucol, a lipid-lowering agent with anti-inflammatory and antioxidant properties, on the biochemical parameters related to oxidative stress, as well as on the behavioral parameters related to motor function in an in vivo HD model based on 3-NP intoxication in rats. Animals were treated with 3.5 mg/kg of probucol in drinking water daily for 2 months and, subsequently, received 3-NP (25 mg/kg i.p.) once a day for 6 days. At the end of the treatments, 3-NP-treated animals showed a significant decrease in body weight, which corresponded with impairment on motor ability, inhibition of mitochondrial complex II activity and oxidative stress in the striatum. Probucol, which did not rescue complex II inhibition, protected against behavioral and striatal biochemical changes induced by 3-NP, attenuating 3-NP-induced motor impairments and striatal oxidative stress. Importantly, probucol was able to increase activity of glutathione peroxidase (GPx), an enzyme important in mediating the detoxification of peroxides in the central nervous system. The major finding of this study was that probucol protected against 3-NP-induced behavioral and striatal biochemical changes without affecting 3-NP-induced mitochondrial complex II inhibition, indicating that long-term probucol treatment resulted in an increased resistance against neurotoxic events (i.e., increased oxidative damage) secondary to mitochondrial dysfunction. These data appeared to be of great relevance when extrapolated to human neurodegenerative processes involving mitochondrial dysfunction and indicates that GPx is an important molecular target involved in the beneficial effects of probucol.
亨廷顿病(HD)是一种常染色体显性遗传性神经退行性疾病,其特征是纹状体和皮质神经元死亡所致的症状。介导 HD 中神经元死亡的分子机制涉及氧化应激和线粒体功能障碍。在啮齿动物中给予 3-硝基丙酸(3-NP),一种线粒体酶琥珀酸脱氢酶的不可逆抑制剂,已被提议作为 HD 的有用实验模型。本研究评估了普罗布考(一种具有抗炎和抗氧化特性的降脂剂)对氧化应激相关生化参数以及对基于大鼠 3-NP 中毒的体内 HD 模型中运动功能相关行为参数的影响。动物每天通过饮用水给予 3.5mg/kg 的普罗布考,持续 2 个月,随后每天腹腔内给予 3-NP(25mg/kg),共 6 天。在治疗结束时,3-NP 处理的动物体重明显下降,这与运动能力受损、线粒体复合物 II 活性抑制和纹状体氧化应激相对应。普罗布考虽然不能挽救复合物 II 的抑制,但能防止 3-NP 引起的行为和纹状体生化变化,减轻 3-NP 引起的运动障碍和纹状体氧化应激。重要的是,普罗布考能够增加谷胱甘肽过氧化物酶(GPx)的活性,GPx 是一种在中枢神经系统中解毒过氧化物的重要酶。本研究的主要发现是,普罗布考能够防止 3-NP 引起的行为和纹状体生化变化,而不影响 3-NP 引起的线粒体复合物 II 抑制,这表明长期普罗布考治疗导致对继发于线粒体功能障碍的神经毒性事件(即增加氧化损伤)的抵抗力增加。当将这些数据外推到涉及线粒体功能障碍的人类神经退行性过程时,这些数据似乎具有重要意义,并表明 GPx 是涉及普罗布考有益作用的重要分子靶标。